NOV-002
- Generic Name
- NOV-002
- Drug Type
- Small Molecule
- Unique Ingredient Identifier
- GY131TX61G
- Background
NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim. It has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.
- Indication
Investigated for use/treatment in breast cancer, lung cancer, and ovarian cancer.
NOV-002 in Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00960726
NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2018-01-02
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 41
- Registration Number
- NCT00499122
- Locations
- ๐บ๐ธ
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States
๐บ๐ธUniversity of Miami, Miami, Florida, United States
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 903
- Registration Number
- NCT00347412
- Locations
- ๐ต๐ฑ
Oddzial Chemioterapii Zaklad Opieki Zdrowotnej MSWiA, Olsztyn, Poland
๐ต๐ฑOddzial Gruzlicy I Chorob Pluc I P, Prabuty, Poland
๐ท๐ดInstitute of Oncology, Department of Medical Oncology II, Bucharest, Romania
Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer
- First Posted Date
- 2006-06-28
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00345540
- Locations
- ๐บ๐ธ
Dana Farber Cancer/Partners Cancer Care, Boston, Massachusetts, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.